MarketCap
Achieve Life Sciences ACHV
$ 7.59
4.69%
Facebook
X
Telegram
Achieve Life Sciences Retained Earnings | ACHV
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Achieve Life Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -260 M | -206 M | -166 M | -136 M | -93.6 M | -60.4 M | -45.7 M | -25.4 M | -12.7 M | -197 M | -177 M | -160 M | -134 M | -102 M | -80.7 M | -66.1 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -12.7 M | -260 M | -120 M |
Quarterly Retained Earnings Achieve Life Sciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -260 M | -270 M | -206 M | -246 M | -231 M | -218 M | -206 M | -193 M | -181 M | -172 M | -166 M | -160 M | -153 M | -145 M | -136 M | -125 M | -112 M | -101 M | -93.6 M | -86.4 M | -79.7 M | -68.4 M | -60.4 M | -60.4 M | -60.4 M | -60.4 M | -45.7 M | -45.7 M | -45.7 M | -45.7 M | -25.4 M | -25.4 M | -25.4 M | -25.4 M | -12.7 M | -12.7 M | -12.7 M | -12.7 M | -2.06 M | -2.06 M | -197 M | -197 M | -177 M | -177 M | -177 M | -177 M | -160 M | -160 M | -160 M | -160 M | -134 M | -134 M | -134 M | -134 M | -102 M | -102 M | -102 M | -102 M | -80.7 M | -80.7 M | -80.7 M | -80.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.06 M | -270 M | -116 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
-421 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
-198 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Qilian International Holding Group Limited
QLI
|
-15.8 M | - | -6.08 % | $ 184 M |  China |
 |
Happiness Biotech Group Limited
HAPP
|
-70.3 M | - | 1.35 % | $ 17.8 M | China |
 |
Synthetic Biologics
SYN
|
-359 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-903 M | - | - | $ 2.02 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-720 M | $ 1.19 | 5.31 % | $ 14.5 M | USA |
 |
Burford Capital Limited
BUR
|
1.8 B | $ 4.37 | 0.23 % | $ 958 M |  Britain |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M | China |
 |
BeyondSpring
BYSI
|
-408 M | $ 0.84 | 34.27 % | $ 34.5 M | USA |
 |
Corner Growth Acquisition Corp.
COOL
|
-6.06 M | - | -0.89 % | $ 114 M | USA |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Cerus Corporation
CERS
|
-1.08 B | $ 2.98 | 4.93 % | $ 568 M | USA |
 |
Compugen Ltd.
CGEN
|
-453 M | $ 2.41 | 4.17 % | $ 225 M |  Israel |
 |
CureVac N.V.
CVAC
|
-1.4 B | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-512 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-325 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
301 M | - | - | $ 4.9 B | Britain |
 |
Завод ДИОД
DIOD
|
1.21 B | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
-307 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-156 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
-246 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
-189 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
-1.01 B | - | 2.43 % | $ 254 M | Germany |
|
Champions Oncology
CSBR
|
-81.1 M | $ 5.1 | 2.63 % | $ 70.5 M | USA |
 |
Affimed N.V.
AFMD
|
-536 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-578 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-350 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
-90 M | $ 3.98 | 1.86 % | $ 2.66 M | USA |
 |
Generation Bio Co.
GBIO
|
-703 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
AnaptysBio
ANAB
|
-773 M | $ 58.47 | 4.37 % | $ 1.68 B | USA |
 |
Anika Therapeutics
ANIK
|
60.8 M | $ 21.5 | 1.56 % | $ 308 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-454 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-1.63 B | - | - | $ 3.37 B | China |
 |
Aurinia Pharmaceuticals
AUPH
|
-649 M | $ 15.47 | 1.91 % | $ 2.08 B | Canada |
 |
GlycoMimetics
GLYC
|
-172 M | - | 9357.83 % | $ 1.01 B | USA |
 |
Aeterna Zentaris
AEZS
|
-20.5 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
-223 M | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bicycle Therapeutics plc
BCYC
|
-900 M | $ 3.9 | 0.24 % | $ 270 M | Britain |
 |
Beam Therapeutics
BEAM
|
-1.64 B | $ 26.75 | 0.91 % | $ 2.65 B | USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
154 M | $ 67.36 | 0.99 % | $ 12.9 B | USA |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |